home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences
Search  -  prev / next
 
 

3rd Annual Cell & Gene Therapy Congress

 
  May 08, 2017  
     
 
Oxford Global, London, UK
6 - 7 November 2017


Oxford Global Conferences presents its 3rd Annual Cell & Gene Therapy Congress, with our co-located 6th Annual Cell Culture & Bioprocessing Congress and 4th Annual Stem Cell Congress and, 6 - 7 of November 2017, London, UK.

View Agenda: bit.ly/2b80uCZ

4 interactive streams:

-          Cell & Gene Therapy: Development & Clinical Trials

-          Cell Therapy Bioprocessing and Manufacturing

Presentations will include cell & gene therapy development, updates in regulatory pathways, commercialisation, bioprocessing and manufacturing.

 

Free Live Webinar 2017:
Regulatory Strategies to Implement your Manufacturing Processes
Presented by Jacqueline Barry, Chief Clinical Officer, Cell Therapy Catapult.

Please Register for Free: bit.ly/2ps3pvG

Free Webinar Recording 2016:
Advances In Gene Editing Technologies
Presented by Richard Morgan, Vice President, Immunotherapy at Bluebird Bio.

Please Register for Free: bit.ly/2pgTI0c


 
 
Organized by: Oxford Global
Invited Speakers:

2017 Cell & Gene Therapy Speakers Include:

Rahul Aras, President, Co-founder & CEO
Juventas Therapeutics

David Sourdive, Co-founder, Executive Vice President
Cellectis

Sven Kili, Vice President and Head of Gene Therapy Development
GlaxoSmithKline

Cedrik Britten, Vice President & Head of Oncology Cell Therapy DPU
GlaxoSmithKline

Markwin Velders, Vice President, Operations
Kite Pharma

Gwendolyn Binder-Scholl, Chief Technology Officer
Adaptimmune

Ajan Reginald, Executive Director & Co-founder
Cell Therapy Ltd

Sylvain Arnould, Process Development & Production Director
Celyad

Alex Bloom, Director, Global Regulatory Affairs
CellMedica

Michael Mercaldi, Director, Purification Process Development and Manufacturing
Codiak Biosciences

Joachim Scholpp, Global Head of Clinical Pharmacology Program Leadership
Boehringer Ingelheim

Katherine Tsokas, Regulatory Head of Regenerative Medicine & Advanced Therapy
Janssen Research & Development

Tanvir Tabish, Head of Drug Product Development for Gene Therapy and Coagulation Factors
Shire

Nitza Thomasson, Chief Preclinical Officer
Gensight Biologics

Emily Culme-Seymour, External Strategy Manager, Gene Therapy, Rare Diseases Unit, R&D
GlaxoSmithKline

Juliana Woda, Project Manager
BioMotiv

Verena Vanessa Fischer, Lab Head in Early Stage Bioprocess Development
Boehringer Ingelheim

Monicah Otieno, Director of Mechanistic & Investigative Toxicology
Janssen

David Schaffer, Director
Berkeley Stem Cell Center, University of California, Berkeley

 
Deadline for Abstracts: N/A
 
Registration: For further information regarding prices and booking details, please contact Guillaume Alonso at g.alonso@oxfordglobal.co.uk or call +44 (0)1865 248 455
E-mail: g.alonso@oxfordglobal.co.uk
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

 
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2017 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.